Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atherolive in Type 2 Diabetes Mellitus
NCT05605704Phase 3Recruiting
- Sponsor
- Université de Monastir
- Start
- Jan 2023
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of atherolive in type 2 diabetes mellitus (T2DM), sponsored by Université de Monastir. Started Jan 2023; status: recruiting.
02
Drugs
atherolive
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05605704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05605704.